TY - JOUR
T1 - Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure
AU - Fragasso, Gabriele
AU - Salerno, Anna
AU - Lattuada, Guido
AU - Cuko, Amarild
AU - Calori, Giliola
AU - Scollo, Antonella
AU - Ragogna, Francesca
AU - Arioli, Francesco
AU - Bassanelli, Giorgio
AU - Spoladore, Roberto
AU - Luzi, Livio
AU - Margonato, Alberto
AU - Perseghin, Gianluca
PY - 2011/9
Y1 - 2011/9
N2 - Objective: Trimetazidine may have beneficial effects on left ventricular (LV) function in patients with systolic heart failure. The authors assessed whether long-term addition of trimetazidine to conventional treatment could improve, along with LV function, resting whole body energy metabolism in patients with chronic systolic heart failure. Design: Single blind randomised study. Setting: University Hospital. Patients: 44 patients with systolic heart failure receiving full medical treatment. Interventions: Indirect calorimetry and two-dimensional echocardiography at baseline and after 3 months. Main outcome measures: Whole body resting energy expenditure (REE), percentage of predicted REE, LV ejection fraction (EF), NYHA class, quality of life. Results: Trimetazidine increased EF compared with conventional therapy alone (from 3568% to 42611% vs from 3567% to 36±6%; p=0.02, analysis of variance for repeated measures). NYHA class and quality of life also improved compared with conventional therapy (p
AB - Objective: Trimetazidine may have beneficial effects on left ventricular (LV) function in patients with systolic heart failure. The authors assessed whether long-term addition of trimetazidine to conventional treatment could improve, along with LV function, resting whole body energy metabolism in patients with chronic systolic heart failure. Design: Single blind randomised study. Setting: University Hospital. Patients: 44 patients with systolic heart failure receiving full medical treatment. Interventions: Indirect calorimetry and two-dimensional echocardiography at baseline and after 3 months. Main outcome measures: Whole body resting energy expenditure (REE), percentage of predicted REE, LV ejection fraction (EF), NYHA class, quality of life. Results: Trimetazidine increased EF compared with conventional therapy alone (from 3568% to 42611% vs from 3567% to 36±6%; p=0.02, analysis of variance for repeated measures). NYHA class and quality of life also improved compared with conventional therapy (p
UR - http://www.scopus.com/inward/record.url?scp=80052180144&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052180144&partnerID=8YFLogxK
U2 - 10.1136/hrt.2011.226332
DO - 10.1136/hrt.2011.226332
M3 - Article
C2 - 21700755
AN - SCOPUS:80052180144
VL - 97
SP - 1495
EP - 1500
JO - Heart
JF - Heart
SN - 1355-6037
IS - 18
ER -